PUBLIC COMPANY

$DSGNDesign Therapeutics, Inc.

Carlsbad, CA, USupdated 1mo ago

SEC EDGAR Yahoo Finance

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 2

Phase 2

DT-168

Fuchs Endothelial Corneal Dystrophy (FECD)

Metabotropic glutamate receptor 4

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Design Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

$DSGN

Active trials

phase2DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophyrecruitingn=28
phase2A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxiarecruitingn=20
phase1A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participantsnot yet recruitingn=36
phase1Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxiacompletedn=32

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

routine RSU / option mechanics (2)

Mar 31, 26grantShapiro David · 60,000 sh
Mar 31, 26grantShapiro David · 7,500 sh

Data sources

SEC EDGAR

last refreshed 11m ago

Found something off?